These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 34818661)

  • 21. Multicentric Castleman disease of hyaline vascular variant presenting with unusual systemic manifestations: a case report.
    Basnayake BMDB; Wazil AWM; Kannangara T; Ratnatunga NVI; Hewamana S; Ameer AM
    J Med Case Rep; 2017 May; 11(1):135. PubMed ID: 28501028
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exuberant cortical thymocyte proliferation mimicking T-lymphoblastic lymphoma within recurrent large inguinal lymph node masses of localized Castleman disease.
    Kansal R; Nathwani BN; Yiakoumis X; Moschogiannis M; Sachanas S; Stefanaki K; Pangalis GA
    Hum Pathol; 2015 Jul; 46(7):1057-61. PubMed ID: 25953658
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Indolent T-lymphoblastic proliferation in association with localized Castleman disease: A case report].
    Chauveau B; Le Loarer F; Bacci J; Baylac F; Dubus P; Ling C; Parrens M
    Ann Pathol; 2019 Feb; 39(1):29-35. PubMed ID: 30554835
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cutaneous involvement as initial presentation of multicentric plasmacytic Castleman disease.
    Chen H; Ba W; Chen H; Yang H
    J Cutan Pathol; 2021 May; 48(5):701-705. PubMed ID: 33469928
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Rare Lymphoproliferative Disease: Castleman Disease.
    Gündüz E; Özdemir N; Bakanay ŞM; Karakuş S
    Turk J Haematol; 2021 Dec; 38(4):314-320. PubMed ID: 34719151
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HHV-8-Associated Multicentric Castleman Disease, a Diagnostic Challenge in a Patient With Acquired Immunodeficiency Syndrome and Fever.
    Dunn R; Jariwal R; Venter F; Mishra S; Bhandohal J; Cobos E; Heidari A
    J Investig Med High Impact Case Rep; 2022; 10():23247096221097526. PubMed ID: 35549932
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnosis of Castleman Disease.
    Szalat R; Munshi NC
    Hematol Oncol Clin North Am; 2018 Feb; 32(1):53-64. PubMed ID: 29157619
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hyaline vascular variant of unicentric Castleman disease of the tonsil: a case report.
    Li P; Liu H; Li H; Li A; Yu G; Yin W
    Diagn Pathol; 2019 Jun; 14(1):70. PubMed ID: 31253137
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Indolent T-lymphoblastic proliferation: a report of three cases.
    Yuanyuan Z; Jianlan X; Yanlin Z; Xiaoge Z
    Virchows Arch; 2022 May; 480(5):1121-1126. PubMed ID: 34482472
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Castleman disease presenting with ophthalmic signs and symptoms.
    Kurokawa T; Suzuki S; Kawaguchi K; Fujisawa N; Yoshimura N
    Am J Ophthalmol; 1999 Jul; 128(1):114-6. PubMed ID: 10482111
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multicentric Castleman disease mimicking IgG4-related disease: A case report.
    Izumi Y; Takeshita H; Moriwaki Y; Hisatomi K; Matsuda M; Yamashita N; Kawahara C; Shigemitsu Y; Iwanaga N; Kawakami A; Kurohama H; Niino D; Ito M; Migita K
    Mod Rheumatol; 2017 Jan; 27(1):174-177. PubMed ID: 25528859
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Afebrile Pneumonia in a Patient With Multicentric Castleman Disease on Siltuximab: Infection Without Fever on Anti-Interleukin-6 Therapy.
    Cohen PR; Nikanjam M; Kato S; Goodman AM; Kurzrock R
    Cureus; 2020 Jul; 12(7):e8967. PubMed ID: 32766009
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease.
    van Rhee F; Rosenthal A; Kanhai K; Martin R; Nishimura K; Hoering A; Fajgenbaum DC
    Blood Adv; 2022 Aug; 6(16):4773-4781. PubMed ID: 35793409
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Unicentric Castlemans disease. Symptoms, diagnostics and therapy.
    Adam Z; Řehák Z; Adamová Z; Koukalová R; Pour L; Krejčí M; Boichuk I; Krejčí M; Štork M; Ševčíková S; Král Z
    Vnitr Lek; 2021; 67(8):465-473. PubMed ID: 35459366
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Historical and pathological overview of Castleman disease.
    Nishimura MF; Nishimura Y; Nishikori A; Yoshino T; Sato Y
    J Clin Exp Hematop; 2022 Jun; 62(2):60-72. PubMed ID: 35474035
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pathology of Castleman Disease.
    Wu D; Lim MS; Jaffe ES
    Hematol Oncol Clin North Am; 2018 Feb; 32(1):37-52. PubMed ID: 29157618
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-Term Tolerance and Efficacy of Siltuximab (Anti-IL-6) in a Young Adult with Idiopathic Multicentric Castleman Disease During COVID-19.
    Bedier H; Isnard S; Maedler-Kron C; Routy JP
    Eur J Case Rep Intern Med; 2023; 10(12):004098. PubMed ID: 38077710
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Castleman disease of plasma cell type accompanied with bronchiolitis obliterans: a case report and review of the literature.
    Zhu Q; Wang S
    J Med Case Rep; 2023 Dec; 17(1):539. PubMed ID: 38082371
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Unicentric Castleman Disease.
    Wong RSM
    Hematol Oncol Clin North Am; 2018 Feb; 32(1):65-73. PubMed ID: 29157620
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Idiopathic multicentric Castleman's disease: a systematic literature review.
    Liu AY; Nabel CS; Finkelman BS; Ruth JR; Kurzrock R; van Rhee F; Krymskaya VP; Kelleher D; Rubenstein AH; Fajgenbaum DC
    Lancet Haematol; 2016 Apr; 3(4):e163-75. PubMed ID: 27063975
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.